HHS Seeks Increase In Sanofi-Aventis’ Fluzone Production
This article was originally published in The Pink Sheet Daily
Executive Summary
HHS is discussing with Sanofi-Aventis whether the company can boost Fluzone production to alleviate an impending flu vaccine shortage.
You may also be interested in...
Chiron To Meet With U.K. Regulatory Authorities On Fluvirin Suspension
The company does not anticipate the three-month manufacturing suspension will be lifted following the Oct. 6 meeting. Chiron's projected 48 mil. doses of flu vaccine were expected to account for nearly 50% of the U.S. supply.
Chiron To Meet With U.K. Regulatory Authorities On Fluvirin Suspension
The company does not anticipate the three-month manufacturing suspension will be lifted following the Oct. 6 meeting. Chiron's projected 48 mil. doses of flu vaccine were expected to account for nearly 50% of the U.S. supply.
Medicare Will Cover Flu Antivirals Under CMS Demonstration Project
The demo will allow CMS to collect data on how drug coverage affects beneficiaries’ health and costs ahead of the Medicare prescription drug benefit in 2006. Bristol’s Symmetrel, Forest’s Flumadine, Gilead’s Tamiflu and GlaxoSmithKline’s Relenza will be covered.